- Home
- PSBD vs URGN Comparison
PSBD vs URGN Comparison
Compare PSBD & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- URGN
- Stock Information
- Founded
- PSBD 2009
- URGN 2004
- Country
- PSBD United States
- URGN United States
- Employees
- PSBD N/A
- URGN N/A
- Industry
- PSBD
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- URGN Health Care
- Exchange
- PSBD Nasdaq
- URGN Nasdaq
- Market Cap
- PSBD 507.0M
- URGN 465.9M
- IPO Year
- PSBD 2024
- URGN 2017
- Fundamental
- Price
- PSBD $13.41
- URGN $11.06
- Analyst Decision
- PSBD Buy
- URGN Strong Buy
- Analyst Count
- PSBD 2
- URGN 6
- Target Price
- PSBD $17.25
- URGN $40.75
- AVG Volume (30 Days)
- PSBD 35.5K
- URGN 418.3K
- Earning Date
- PSBD 05-06-2025
- URGN 03-10-2025
- Dividend Yield
- PSBD 13.00%
- URGN N/A
- EPS Growth
- PSBD N/A
- URGN N/A
- EPS
- PSBD N/A
- URGN N/A
- Revenue
- PSBD N/A
- URGN $90,398,000.00
- Revenue This Year
- PSBD N/A
- URGN $43.60
- Revenue Next Year
- PSBD N/A
- URGN $103.77
- P/E Ratio
- PSBD N/A
- URGN N/A
- Revenue Growth
- PSBD N/A
- URGN 9.29
- 52 Week Low
- PSBD $13.32
- URGN $9.03
- 52 Week High
- PSBD $17.02
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- PSBD 20.55
- URGN 50.86
- Support Level
- PSBD $13.53
- URGN $11.12
- Resistance Level
- PSBD $14.61
- URGN $11.91
- Average True Range (ATR)
- PSBD 0.55
- URGN 0.57
- MACD
- PSBD -0.08
- URGN -0.02
- Stochastic Oscillator
- PSBD 0.00
- URGN 26.40
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.